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Abstract Although embryonal proteins have been used as
tumor marker, most are not useful for detection of early ma-
lignancy. In the present study, we developed mouse monoclo-
nal antibodies against fetal lung of miniature swine, and
screened them to find an embryonal protein that is produced
at the early stage of malignancy, focusing on lung adenocar-
cinoma. We found an antibody clone that specifically stained
stroma of lung adenocarcinoma. LC-MS/MS identified the
protein recognized by this clone as dimethylarginine
dimethylaminohydrolase 2 (DDAH2), an enzyme known for
antiatherosclerotic activity. DDAH2 was found to be
expressed in fibroblasts of stroma of malignancies, with
higher expression in minimally invasive adenocarcinoma
(MIA) and invasive adenocarcinoma than in adenocarcinoma
in situ (AIS). Moreover, tumors with high stromal expression
of DDAH2 had a poorer prognosis than those without. In vitro
analysis showed that DDAH2 increases expression of endo-
thelial nitric oxide synthase (eNOS), inducing proliferation
and capillary-like tube formation of vascular endothelial cells.
In resected human tissues, eNOS also showed higher expres-
sion in invasive adenocarcinoma than in AIS and normal lung,
similarly to DDAH2. Our data indicate that expression of
DDAH2 is associated with invasiveness of lung adenocarci-
noma via tumor angiogenesis. DDAH2 expression might be a
prognostic factor in lung adenocarcinoma.
Keywords DDAH2 . Angiogenesis . Adenocarcinoma .
Malignant stroma . Prognosis
Introduction
Lung cancer is the leading cause of cancer-related death
worldwide. Because most patients are diagnosed at an ad-
vanced stage, the prognosis of lung cancer remains poor. Lung
adenocarcinoma is the most frequent histological type of lung
cancer in Japan and is increasing in the USA and most Euro-
pean countries [1, 2].
Recently, a multidisciplinary classification of lung adeno-
carcinoma has been published, in which several new concepts,
such as adenocarcinoma in situ (AIS) and minimally invasive
adenocarcinoma (MIA), have been newly defined [3, 4]. AIS
shows replacement growth of tumor cells along alveolar struc-
tures (lepidic growth) and contains no invasive component.
Although MIA has been added to the invasive adenocarcino-
ma category, its area of invasion is very limited and it is con-
sidered as very early stage adenocarcinoma. Therefore, it has
been suggested that MIA has a prognosis as favorable as that
of AIS. AIS and MIA are usually detected accidentally or by
CT screening, and it is assumed that their biological charac-
teristics are different from those of overt invasive adenocarci-
noma. The current classification has focused interest on the
concept of stepwise progression of peripheral type adenocar-
cinoma [5]. It is very important to compare the biological
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features of AIS and MIAwith those of overt invasive adeno-
carcinoma, in order to clarify molecular mechanisms involved
in malignant progression of lung adenocarcinoma.
With regard to the detection and diagnosis of lung adeno-
carcinoma by immunohistochemistry, various tumor biomark-
er proteins have been reported. These biomarker proteins are
classified into several types according to their characteristics
and include oncogenic, tissue- and/or cell-specific, and em-
bryonic proteins. Epidermal growth factor receptor (EGFR),
Her2, B-raf, Ret, Ros and anaplastic lymphoma kinase (ALK)
are examples of oncogenic biomarkers associated with prog-
nosis [6–8]. The expression status of these oncogenes also has
an important bearing on the selection of targeted therapeutic
drugs, since various types of tyrosine kinase inhibitors are
available. On the other hand, tissue- and/or cell-specific bio-
markers include cyto-keratins (AE1/AE3, CK7, CK20, etc.),
membrane markers of lymphocytes (CD20, CD79, CD3,
CD4, CD8, CD9, etc.) and differentiation-specific markers
such as TTF-1 for alveolar epithelial differentiation. Although
tissue- and/or cell-specific biomarkers are suitable for differ-
ential diagnosis between cancer and lymphoma, or between
lung adenocarcinoma and metastatic adenocarcinoma, they
are not useful as indicators of malignancy.
Although it is noteworthy that these tumor biomarkers in-
clude embryonic and fetal proteins such as carcinoembryonic
antigen (CEA), OCT3/4, and SOX2 [9–11], few attempts have
been made to search for fetal biomarkers systematically. Ex-
perimental use of human fetal tissue has various associated
ethical issues. Fortunately, most antibodies against swine tis-
sue cross-react with human tissue, since swine messenger
RNA (mRNA) has more than 80 % homology with its human
counterpart. In view of this homology, fetal swine tissue con-
stitutes an ideal antigenic material for producing antibodies
reactive with human fetal tissue and human cancer tissue as
embryonic biomarker.
In the present study, we immunized mice against fetal
swine tissue and produced monoclonal antibodies (mAbs)
reactive with human lung adenocarcinoma. One reacted char-
acteristically with the stromal region of human lung adeno-
carcinoma, and the antigen was identified as dimethylarginine
dimethylaminohydrolase 2 (DDAH2) by LC/MS-MS analy-
sis. We demonstrate that DDAH2 is a marker of tumor an-
giogenesis and is expressed in lung adenocarcinoma at an
early stage.
Materials and methods
Patient selection
We selected 133 cases of lung adenocarcinoma that had been
resected at Tsukuba University Hospital (Ibaraki, Japan) be-
tween 2002 and 2013. All patients had given informed
consent for study of their materials before collection. The
adenocarcinomas were classified according to the World
Health Organization (WHO) classification (fourth edition)
and the UICC TNM classification of malignant tumors (sev-
enth edition) [12]. The patients’ clinicopathological character-
istics are summarized in Supplementary Table 1.
Production of monoclonal antibodies
The normal length of gestation period in swine is approxi-
mately 16 weeks. So, we selected normal fetuses of CLAWN
strain miniature swine (Japan Farm CLAWN Institute, Kago-
shima, Japan) at weeks 7 and 13 of gestation, and they were
harvested surgically from maternal swine. Fetal lungs were
resected and embedded in Tissue-Tek OCT Compound
(Sakura Finetek Japan, Tokyo, Japan), quickly frozen, and
stored at −80 °C. Protein extraction was performed using T-
PER™ Tissue Protein Extraction Reagent (Thermo Scientific,
Rockford, IL) with protease inhibitor cocktail (Sigma-Al-
drich, St. Louis, MO). Protein concentration was determined
using a bicinchoninic acid protein assay (Thermo Scientific)
with bovine serum albumin as the standard. Antigen was pre-
pared as a mixture of extracted protein and an equivalent
amount of complete Freund’s adjuvant (CFA) (Sigma-Al-
drich). CFA/antigen emulsion was injected subcutaneously
into the bilateral footpad of a 5-week-old BALB/c mouse on
day 1, and again on day 10. On day 14, bilateral popliteal
lymph node cells were harvested and fused with the murine
myeloma cell line Sp2/0 using polyethylene glycol. Hybrid-
omas were selectively cultured and cloned using the methyl-
cellulose method in a 10 % incubator at 37 °C. Fusion, selec-
tion, and cloning were performed with a ClonaCell®-HY Hy-
bridoma Cloning Kit (Stemcell Technologies, Vancouver,
British Columbia, Canada) in accordance with the manufac-
turer’s protocol. The isolated hybridoma colonies were each
suspended in individual wells of a 96-well plate.
Antigen characterization
The immunoglobulin isotype and subtype of the selected hy-
bridoma clone was determined using a Mouse Monoclonal
Antibody Isotyping Test Kit (AbD Serotec, Kidlington, UK).
A lung adenocarcinoma cell line (Calu-3) was used for
Western blotting and immunoprecipitation (IP). Calu-3 was
purchased from the American Type Culture Collection (Ma-
nassas, VA). Total protein was extracted fromCalu-3 usingM-
PER mammalian protein extraction reagent (Thermo Scientif-
ic) and from frozen tissue of surgically resected lung adeno-
carcinoma with T-PER. Extracted proteins were denatured at
95 °C for 5 min, separated by SDS polyacrylamide gel elec-
trophoresis (SDS-PAGE) under reducing conditions, and
transferred to PVDF membranes using an iBlot Gel Transfer
System (Life Technologies Japan, Tokyo, Japan). After
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blocking, the membranes were incubated with purified mono-
clonal antibody (2 μl/ml) as the primary antibody for 1 h at
room temperature. Antigen protein was detected using HRP-
conjugated anti-mouse Igs (Thermo Scientific), and the pro-
tein bands were visualized with SuperSignal West Dura ex-
tended duration substrate (Thermo Scientific) and X-ray film
(Kodak, Rochester, NY).
Antigen protein that had reacted with the selected mono-
clonal antibody was immunoprecipitated from extracted total
protein of frozen lung adenocarcinoma tissue with a Co-
Immunoprecipitation Kit (Thermo Scientific), in accordance
with manufacturer’s protocol. Briefly, the purified monoclo-
nal antibody was immobilized on beads in a column, and
then, the extracted total protein was incubated with the beads
at 4 °C for 2 h. After washing, the immunoprecipitate was
eluted with acidic buffer (pH 2.8). The eluted fraction con-
taining the antigen was denatured, separated by SDS-PAGE
under reducing conditions, and stained with silver. The pro-
tein band indicating the antigen identified by matching with
the Western blot was excised and cut into pieces. The excised
gel piece was digested with modified porcine trypsin (Ther-
mo Scientific), and the processed peptides were subjected to
LC/MS/MS analysis with a Zaprous LC/MS system (AMR)
at the National Institute for Materials Science (Tsukuba, Ja-
pan). The obtained data file was searched against the SWISS-
Prot database using MASCOT MS/MS Ion Search (Matrix
Science, London, UK).
Immunohistochemistry for DDAH2 using hybridoma
supernatant
All samples were fixed with 10 % formalin and embedded in
paraffin. After deparaffinization, the samples were placed in
blocking solution to suppress nonspecific staining for 30 min.
Then, antigen retrieval was performed using citrate buffer (pH
6.0) in an autoclave at 121 °C for 15 min. The culture super-
natant of the hybridoma that detected DDAH2was used as the
primary antibody, and incubation was for 60 min at room
temperature, followed by incubation with the secondary anti-
body (EnVision kit; Dako, Tokyo, Japan) for 30 min at room
temperature. Diaminobenzidine chromogen solution (Dako)
was applied to the slides, followed by counterstaining with
hematoxylin. Immunohistochemistry for endothelial nitric ox-
ide synthase (eNOS) and CD31 were performed in the same
way, using anti-eNOS antibody at dilution of 1:75 (ab5589,
Abcam, Cambridge, UK), and anti-CD31 antibody at dilution
of 1:125 (ab28364, Abcam), respectively.
The staining was judged by focusing on the tumor stroma,
and normal vascular endothelium was used as a control. If an
area, showing staining similar to or stronger than that in the
control, exceeded 5 % of the total tumor stroma, we defined
the staining as “positive.” We further divided positive sam-
ples into two groups as follows: “DDAH2-strong” with a
positive area stronger than the control evident in 30 % or
more of the stroma, and “DDAH2-weak” with a positive area
of less than 30 %.
DDAH2 in situ hybridization
To identify cells that secreted DDAH2, in situ hybridization
was performed as reported previously [13]. The details of in
situ hybridization are described in the supplementary
information.
Western blot analysis of DDAH2 and eNOS
Protein extraction from surgically resected specimens was per-
formed using T-PER reagent (Pierce, Rockford, IL). Western
blotting for DDAH2 was performed using the same protocol
as that described above. Western blotting for eNOS was per-
formed as follows. Twenty micrograms of extracted protein
was mixed with Laemmli sample buffer, denatured at 95 °C
for 5 min, and electrophoresed on 7.5%Mini Protein TGX gel
(Bio-Rad Laboratories, Hercules, CA). Proteins were trans-
ferred to polyvinylidene difluoride (PVDF) membranes using
an iBlot™ gel transfer system (Life Technologies Japan). The
membranes were blocked with 0.1 % blocking reagent and
then incubated with anti-eNOS antibody at dilution of
1:1000 (ab5589, Abcam) at 4 °C overnight. After washing,
immunoreactivity was detected with specific secondary anti-
bodies conjugated to horseradish peroxidase. The protein
bands were visualized using Supersignal West Femto maxi-
mum sensitivity substrate (Thermo Scientific) and X-ray film
(BioMax Light film; Kodak, Rochester, NY).
Cell culture and reagents
Human umbilical vein endothelial cells (HUVECs) were cul-
tured to evaluate the effect of DDAH2 on angiogenesis
in vitro. The details are described in the supplementary
information.
Proliferation and capillary-like tube formation assay
The details of endothelial cell proliferation and capillary-like
tube formation assay are described in the supplementary
information.
Capillary-like tube formation assay
To evaluate migration of endothelial cells, we examined
capillary-like tube formation by the Geltrex™ angiogenesis
assay in accordance with manufacturer’s protocol. Briefly,
Geltrex™ was added to the growth surface and incubated for
30 min at 37 °C to allow the gel to solidify. HUVEC were
gently added to each Geltrex™ coated 24-well plate at 5×104
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cells per well in growth medium. Then, DDAH2 recombinant
protein or PBS (as control) was added. HUVECwere incubat-
ed for 6 h at 37 °C in an atmosphere containing 5 % CO2. The
cells were visualized directly using a light microscope, and the
mean tube length was measured.
Statistical analysis
Statistical analysis was performed using JMP 9 software. Sta-
tistical comparisons between groups were performed using
one-way analysis of variance (ANOVA) followed by Stu-
dent’s t test. Disease-free survival (DFS) withDDAH2 expres-
sion was compared using the Kaplan-Meier method, and the
significance of differences between survival curves was
assessed using log-rank test. DFS was determined from the
date of surgery until the date of recurrence or last follow-up.
Statistical significance was defined as p<0.05.
Results
Screening for mouse monoclonal antibodies
Ninety-seven hybridoma clones were obtained, and the hy-
bridoma supernatants were used for immunohistochemical
screening in two steps. As the first screening, we selected
clones that were reactive with fetal but not with mature swine
lung (Fig. 1a, b) and obtained 39 clones. We then selected
antibodies reactive with lung adenocarcinoma but nonreactive
with normal lung tissue, and obtained 11 clones. Of these
clones, six showed cytoplasmic staining of cancer cells, but
not with normal lung tissue. Four clones showed cytoplasmic
staining of cancer cells but also nuclear staining of alveolar
t y p e I I c e l l s i n no rma l l ung t i s s u e . We th en
immunohistochemically tested these clones on more than
100 adenocarcinomas and found that specificity for lung ade-
nocarcinoma was low. One clone showed specific reactivity
with cancer stroma but not with cancer cells (Fig. 1c, d). Be-
cause this pattern of reactivity was very characteristic, we
selected this clone for further analysis.
Identification of dimethylarginine
dimethylaminohydrolase 2
UsingWestern blotting, the clone was not reactive with a lung
adenocarcinoma cell line (Calu-3) but the sample of lung ad-
enocarcinoma showed a positive band at approximately
30 kDa (Fig. 1e). By immunoprecipitation, we then isolated
the recognized antigen in frozen human lung adenocarcinoma
tissue, and identified this using LC-MS/MS as DDAH2.
DDAH2 expression in lung adenocarcinoma
DDAH2 diffusely stained cancer stroma, but the expressing
cells could not be identified. Using in situ hybridization, we
identified the cells expressing DDAH2 as fibroblasts in the
malignant stroma (Fig. 2a–c). Using immunohistochemistry,
we then examined expression of DDAH2 on 133 cases of sur-
gically resected lung adenocarcinoma. The stroma of lung ad-
enocarcinoma showed diffuse staining for DDAH2, whereas
tumor cells themselves were not stained (Fig. 2d–f). On the
other hand, in normal lung tissue, only vascular endothelium
showed staining for DDAH2. Table 1 summarizes the propor-
tion of DDAH2-positive cases for each histological subtype of
lung cancer. Interestingly, almost all cases of MIA and invasive
adenocarcinoma were positive for DDAH2 (MIA 100 %; inva-
sive adenocarcinoma 99 %), while only half of pre-invasive
lesions were positive (AAH and AIS 46 %). The staining in-
tensity was not clearly associated with histological evidence of
invasion in the pleura or in vessels, or proliferating fibroblasts.
DDAH2 expression and patient outcome
We assessed association of DDAH2 expression with patient
outcome. We selected 61 pathological stage I cases of which
details of the postoperative course were available. The sam-
ples were divided into a DDAH2-strong group (Fig. 3a, n=26)
and a DDAH2-weak group (Fig. 3b, n=35). The Kaplan-
Meier curves showed a significant difference in DFS between
the DDAH2-strong and DDAH2-weak groups (p=0.026,
Fig. 3c). High expression of DDAH2 was significantly asso-
ciated with poor outcome.
DDAH2 and tumor angiogenesis
We next examined whether DDAH2 might be a prognostic
factor for lung adenocarcinoma. We hypothesized that
DDAH2 contributes to lung adenocarcinoma invasion
through tumor angiogenesis via NO production (Fig. 4a) and
expected that eNOS expression might increase upon stimula-
tion by DDAH2. Expression of both DDAH2 and eNOS by
Western blotting on seven surgically resected specimens,
showed both to be expressed at a significantly higher level
in invasive adenocarcinoma than in AIS and normal lung
(Fig. 4b). By IHC, we confirmed high expression of eNOS
in invasive adenocarcinoma compared to AIS and normal
lung, using ten invasive adenocarcinomas, five AIS, and five
normal lung tissues. Interestingly, eNOS was expressed
strongly in vascular endothelium of malignant stroma
(Fig. 4c, d), whereas vascular endothelium of normal lung
was negative or showed only faint staining (Fig. 4e, f). These
data indicate that DDAH2 stimulated production of eNOS is
significantly higher in invasive adenocarcinoma than in AIS
and normal tissue.
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To determine whether DDAH2 regulates angiogenesis
through NO production, we next examined the angiogenic
effect of DDAH2 in vitro. We first confirmed by Western
blotting that DDAH2 recombinant protein significantly
enhances eNOS expression in HUVEC (data not shown).
We then found that recombinant DDAH2 protein significantly
increases the number of HUVEC in a dose-dependent manner
(Fig. 5a, c). We also examined the effect of DDAH2 on
Fig. 1 Immunohistochemical screening using culture supernatant of
hybridoma clones. Initial screening was performed using swine lung
tissues, and we selected clones that positively recognized antigens in
fetal miniature swine lung (a) and were unreactive with mature swine
lung (b). In the second screening, normal lung tissue and small lung
adenocarcinoma were used and the clones reactive only with lung
adenocarcinoma were selected. c Absence of staining in normal human
lung. d Staining of tumor stroma of lung adenocarcinoma. e Western
blotting using the selected hybridoma supernatant as the primary
antibody. Protein bands were detected at approximately 30 kDa with
protein extracted from frozen lung adenocarcinoma specimens (1), but
not from the lung cancer cell line, Calu-3 (2)
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HUVEC tube formation in an in vitro angiogenesis model. As
shown in Fig. 5b, d, DDAH2 recombinant protein significant-
ly enhances capillary-like tube formation in comparison with
the control group. Taken together, our findings suggest that
DDAH2 promotes tumor angiogenesis in lung adenocarcino-
ma by increasing the production of NO.
Fig. 2 In situ hybridization (ISH) of DDAH2 mRNA using lepidic-
predominant invasive adenocarcinoma. a Fibroblasts in tumor stroma
(HE stain). b Fibroblasts are reactive for DDAH2 mRNAwith antisense
cRNA probe. c No reactivity was found when a sense-cRNA probe of
DDAH2 mRNA was used. Immunohistochemistry for DDAH2 in lung
adenocarcinoma. d Representative case of adenocarcinoma showing a
lepidic growth pattern. e DDAH2-IHC (×10) and (f) DDAH2-IHC
(×40); the tumor stroma diffusely stains whereas tumor cells are negative
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Discussion
DDAH2 is one of the embryonal proteins expressed in several
fetal tissues such as fetal lung and fetal kidney [14]. DDAH2
is expressed mainly in the heart, kidney, and placenta, where it
serves as an antiatherosclerotic factor. Asymmetric
dimethylarginine (ADMA) is an endogenous inhibitor of
eNOS, and DDAH2 metabolizes ADMA to dimethylamine
and L-citrulline. DDAH2 activity increases the expression of
eNOS, resulting in promotion of vasodilation and
vasoprotective activity. In the cardiovascular and renovascular
systems, previous studies report that DDAH/ADMA pathway
act as a key regulator of angiogenesis through control of en-
dothelial NO production [15, 16].
We developed a monoclonal antibody specifically reacting
with stroma of lung adenocarcinoma, and identified the recog-
nized antigen as DDAH2. DDAH2 is one of the embryonal
Tab l e 1 P r o p o r t i o n o f p o s i t i v e c a s e s f o r DDAH2
immunohistochemistry
Histological subtypes Positive cases
Preinvasive lesion 21/47 (46 %)
Atypical adenomatous hyperplasia (AAH) 2/14
Adenocarcinoma in situ (AIS) 19/33
Minimally invasive adenocarcinoma (MIA) 11/11 (100 %)
Invasive adenocarcinoma 74/75 (99 %)
Lepidic predominant 40/41
Acinar predominant 7/7
Papillary predominant 8/8
Micropapillary predominant 1/1
Solid predominant 18/18
Fig. 3 Based on intensity of immunohistochemical staining, 61 cases of stage I adenocarcinoma were divided into (a) DDAH2-strong and (b) DDAH2-
weak. c Kaplan-Meier analysis of disease-free survival using log-rank test
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Fig. 4 DDAH2 promotes tumor angiogenesis through NO production in
lung adenocarcinoma. a Tumor fibroblast-derived DDAH2 increases
expression of eNOS in vascular endothelial cells, and enhances NO
production, followed by upregulation of the kinase cascade. This
pathway stimulates endothelial cell proliferation and migration and
results in angiogenesis. b Samples of normal lung (n=1), AIS (n=1),
and invasive adenocarcinoma (n=5) were prepared and used for
Western blot analysis with antibodies against DDAH2 and eNOS.
Immunohistochemistry with anti-eNOS antibody was performed using
the same samples as those used for Western blotting. Vascular
endothelial cells were subjected to immunohistochemistry with anti-
CD31 antibody. c eNOS was expressed strongly in vascular
endothelium of the invasive adenocarcinoma. d Immunohistochemistry
with anti-CD31 antibody in the same section as c. e The vascular
endothelial cells of normal lung were negative for eNOS. f
Immunohistochemistry with anti-CD31 antibody in the same section as e
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proteins highly expressed in several fetal tissues, including lung
and kidney. In hypoplastic human fetal lung, vascular endotheli-
um showed significantly decreased expression of both CD31 and
eNOS relative to normal control tissue [17]. It has been suggested
that the DDAH2-eNOS pathway plays an important role in the
process of angiogenesis in fetal lung. On the other hand, DDAH2
is also regarded as an antiatherosclerotic factor in adults because
DDAH2 increases the production of NO, which promotes vaso-
dilation and angiogenesis. Although impairment or decreased
expression of DDAH2 has been reported in several diseases such
as chronic kidney disease, pulmonary hypertension, and cardio-
vascular disease [18–22], the association of DDAH2with malig-
nancy has received less attention.
We initially examined expression of DDAH2 in lung adeno-
carcinomas using immunohistochemistry and found a signifi-
cant difference in the proportion of DDAH2-positive cases be-
tween MIA, invasive adenocarcinoma, and preinvasive lesions.
DDAH2 was expressed in most invasive adenocarcinomas, but
only about half of the AIS cases showed DDAH2 staining.
Because most lung adenocarcinomas develop in a stepwise
manner from AAH to AIS, and then from MIA to invasive
adenocarcinoma, it has been suggested that DDAH2might play
an important role in the progression of lung adenocarcinoma,
especially in the early phases of tumor invasion. Moreover, we
found a statistically significant correlation between the intensity
of immunohistochemical staining for DDAH2 and DFS. This
suggests that DDAH2 might be a novel prognostic indicator in
lung adenocarcinoma and useful for the detection of early in-
vasive adenocarcinoma such as MIA.
We hypothesized that DDAH2 contributes to lung adenocar-
cinoma invasion through promotion of tumor angiogenesis. As
shown in Fig. 4a, expression of tumor fibroblast-derived
DDAH2 in vascular endothelium led to an increase of NO pro-
duction, followed by increased vascular endothelial cell prolifer-
ation and migration. Angiogenesis is an important process for
tumor growth, and several therapeutic strategies targeting tumor
angiogenesis have been developed [23–25]. Only a few previous
studies have investigated the function of DDAH in malignant
tumors. Kostourou et al. reported that overexpression of DDAH1
is associated with increased neovascularization of gliomas
in vivo, and Vanella et al. suggested that DDAH2 might contrib-
ute to tumor angiogenesis in prostate cancer through an increase
of NO production [26, 27]. Both studies suggest an angiogenic
effect of DDAH in malignant tumors. Against this background,
we initially examined expression of DDAH2 and eNOS in sur-
gical specimens. eNOS was more highly expressed in invasive
adenocarcinoma than in normal tissue or AIS, reflecting the pat-
tern of DDAH2 expression. We then showed that DDAH2 sig-
nificantly promotes proliferation and capillary-like tube forma-
tion of endothelial cells in vitro. These results suggest that tumor
angiogenesis in invasive adenocarcinoma is at least partially ac-
tivated by DDAH2. It is of considerable interest that DDAH2
accelerates the progression of lung adenocarcinoma whereas it
works as a preventive factor against cardiovascular and chronic
kidney diseases.
One of the noteworthy findings of this studywas that DDAH2
is expressed in cancer-associated fibroblasts (CAF) of lung ade-
nocarcinoma. CAF are activated fibroblasts observed in the stro-
ma of various solid tumors. CAF are a major constituent of
reactive tumor stroma and play a crucial role in tumor progres-
sion and metastasis [28, 29]. Recently, emerging evidence has
suggested that CAF also promote tumor angiogenesis in breast
and colon cancer by secreting angiogenic factors [30, 31]. In lung
adenocarcinoma, previous reports have indicated that CAF play
an important role in cancer progression and that their presence is
correlatedwith poor prognosis [32, 33]. However, a role for CAF
in angiogenesis in lung adenocarcinoma has not been well char-
acterized. We observed diffuse staining of DDAH2 in cancer
stroma and detected expression of DDAH2 mRNA in CAF of
lung adenocarcinoma by in situ hybridization.We also found that
DDAH2 derived from CAF promotes tumor angiogenesis in
lung adenocarcinoma. These results suggest that CAF contribute
to tumor angiogenesis in lung adenocarcinoma by secreting
DDAH2.
In lung cancer, the angiogenic vascular endothelial growth
factor (VEGF) is expressed mainly in tumor cells, and
bevacizumab, a humanized anti-VEGF monoclonal antibody,
has been developed and is applied as systemic therapy in patients
with nonsmall cell lung cancer, with the exception of squamous
cell carcinoma [34–36]. However, for control of tumor angiogen-
esis in lung cancer inhibition of VEGF only is insufficient. Pos-
sible functional relationships between VEGF and DDAH2 in
lung adenocarcinoma need to be studied. During tumor angio-
genesis, VEGF stimulates NO production via activation of the
PI3K/Akt cascade, which is distinct from the DDAH/ADMA
pathway [37, 38]. Several reports have described a role of
DDAH2 in regulating VEGF expression. Hasegawa et al. report-
ed that DDAH2 stimulates expression of VEGF through the
transcription factor Sp1 in vascular endothelial cells, and Xiao
et al. reported that expression of VEGF mRNA in endothelial
cells is significantly suppressed by DDAH2 siRNA [39, 40].
These data suggest that DDAH2 exerts dual effects on NO-
mediated angiogenesis. DDAH2 may act not only on vascular
endothelial cells by releasing them from ADMA-induced eNOS
inhibition but also on tumor cells by stimulating their expression
of VEGF. Inhibition of DDAH2 activity in lung adenocarcinoma
may therefore become a promising therapeutic strategy
complementing conventional antiangiogenic therapy.
We show that DDAH2 plays an important role in tumor an-
giogenesis in lung adenocarcinoma.However, themechanism by
which DDAH2 expression is regulated in malignant stroma re-
mains unclear. Malignant stroma is an aberrant microenviron-
ment, characterized by persistent hypoxic conditions. Hypoxia
is one of the major features of solid tumors, favoring tumor
progression and increasing the degree of tumor resistance to
treatment [41, 42]. Emerging evidence suggests that hypoxia-
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inducible signaling pathways are significantly associated with
tumor angiogenesis [43, 44]. Among the major transcription
regulators involved in the response to hypoxic conditions,
hypoxia-inducible factor (HIF) plays an important role in tumor
angiogenesis, invasion, and metastasis. HIF promotes tumor
angiogenesis through activation of downstream genes, such as
VEGF and angiopoetin-2 (Ang-2) [45, 46]. Although the asso-
ciation between hypoxia and DDAH2 is still unclear, DDAH2
might be regulated by HIF, as well as other angiogenic factors.
Pullamsetti et al. reported that in murine pulmonary fibrosis
transforming growth factor-β1 (TGF-β1) expressed by lung
epithelial cells increases the expression of DDAH2 in a time-
dependent manner [47]. TGF-β1 is considered to be one of the
key regulators of tumor progression, notably in the process of
epithelial-mesenchymal transition (EMT) [48]. Several reports
have suggested that TGF-β1 also accelerates tumor angiogen-
esis [49, 50]. These molecules might be potential regulators of
DDAH2 in malignant stroma, and further studies aimed at
clarifying the mechanism of DDAH2 regulation are needed.
In conclusion, DDAH2 is expressed in CAF in early stage
lung adenocarcinoma and might play an important role in
tumor invasion by promoting tumor angiogenesis through an
increase of NO production. It also might be a novel prognostic
factor in lung adenocarcinoma. To elucidate the mechanisms
involved in vivo studies will be necessary. The therapeutic
potential of DDAH2 as target for inhibition of tumor angio-
genesis in lung adenocarcinoma, complementary to conven-
tional antiangiogenic therapy, merits to be explored.
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